Mommert, Marine
,
Tabone, Olivier
Guichard, Audrey
Oriol, Guy
Cerrato, Elisabeth
Denizot, Mélanie
Cheynet, Valérie
Pachot, Alexandre
Lepape, Alain
Monneret, Guillaume
Venet, Fabienne
Brengel-Pesce, Karen
Textoris, Julien
Mallet, François
,
Funding for this research was provided by:
Agence Nationale de la Recherche et de la Technologie
Article History
Received: 1 August 2019
Accepted: 14 February 2020
First Online: 18 March 2020
Ethics approval and consent to participate
: Immunosepsis cohort subsetPatients were included from a cohort of adult septic shock patients enrolled from December 2001 to April 2005 in two ICUs from a French university hospital. The clinical study was approved by the regional ethics committee (Comité Consultatif de Protection des Personnes dans la Recherche BioMédicale de Lyon A), which waived the need for written informed consent because the study was observational, with a low risk to the patients, and no specific procedure, other than routine blood sampling, was required. Oral information and non-opposition to inclusion in the study were mandatory and were systematically obtained before any blood sample was drawn. This was recorded in patients’ clinical files.MIP-Rea cohort subsetThe study was approved by our institutional ethical review board (Comité d’Ethique des Centres d’investigation Clinique de l’Inter-Région Rhône-Alpes Auvergne – IRB 5044), and consent for an ancillary study was obtained a posteriori. The protocol of this ancillary retrospective study was submitted to the French CCTIRS and CNIL committees and approved on April 22, 2016, and September 30, 2016, respectively. Further, informed consent was received from patients for inclusion in this specific study.
: Not applicable
: MM, AG, GO, EC, VC, AP, KBP, JT, and FM are employees of bioMérieux, an in vitro diagnostic company. All other authors declare that they have no competing interests.